Log In Get Started
Press Releases May 15, 2026 08:30 AM

Cormedix Therapeutics to Participate in two Upcoming Investor Conferences

CorMedix Therapeutics to Present at The RBC Capital Markets and Jefferies Global Healthcare Conferences

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
CRMD

CorMedix Therapeutics announced that its management team will participate in investor conferences hosted by RBC Capital Markets and Jefferies in May and June 2026, where they will engage in fireside chats and investor meetings to discuss the company's developments and strategies in the biopharmaceutical sector focused on life-threatening conditions in the U.S.

Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
CRMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CorMedix will participate in two major healthcare conferences in New York in May and June 2026, engaging with investors and industry stakeholders.
  • The company's focus continues to be on developing and commercializing therapeutic products for prevention and treatment of serious health conditions within institutional care settings in the U.S.
  • CorMedix has an established commercial and medical infrastructure in hospitals, clinics, and infusion centers to support the marketing and sales of its products.

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026 and the Jefferies Global Healthcare Conference being held in New York on June 2 – 4, 2026. Details for each fireside chat is as follows:

RBC Capital Markets Global Healthcare Conference
Date:Wednesday, May 20, 2026Time:11:00am EDTWebcast:Click here


Jefferies Global Healthcare Conference
Date:Wednesday, June 3, 2026Time:4:20pm EDTWebcast:Click here


About CorMedix

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers.  For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576


Risks

  • Participation in investor conferences does not guarantee new funding or positive investor sentiment, which can affect stock performance in the biotech sector.
  • The biopharmaceutical industry faces regulatory and clinical trial risks that may impact CorMedix's product development and commercialization timelines.
  • Market adoption and reimbursement challenges in institutional healthcare settings could limit the company's sales growth and revenue generation.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026